NeoStem trades up again today off its switch to NASDAQ; names new Chief Medical Officer


NeoStem (NBS +6.7%) trades up again today after the cellular therapy company switched to the NASDAQ Stock Market from the NYSE yesterday.

Additionally, it's also named Dr. Douglas W. Losordo as its chief medical officer.

Dr. Losordo most recently was vice president of New Therapies Development, Regenerative Medicine and Baxter Ventures at Baxter International.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs